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Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in
post-menopausal women, the current evidence strongly supports the view that AIs should be used 2–3 years after tamoxifen to
achieve the maximal overall survival (OS) advantage.
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The last year has been an interesting time for oncologists
interested in the adjuvant hormonal treatment of post-menopausal
women with receptor-positive early breast cancer. Three important
new pieces of clinical research were presented at the 2008 San
Antonio Breast Cancer Symposium: a meta-analysis of the
Aromatase Inhibitor (AI) trials (Ingle et al, 2008b) and two
individual AI studies (Jakesz et al, 2008; Mouridsen et al, 2008).
These data suggest that it may be premature for oncologists to
discard tamoxifen. In this mini review, we analyse whether all
patients should be exposed to 2 or 3 years of tamoxifen as part of
their adjuvant hormone therapy for receptor-positive early-stage
breast cancer.
Improved mortality from breast cancer during the past two
decades has been partly attributed to increased use of adjuvant
hormonal treatment. The Oxford Overviews showed that tamox-
ifen, an oestrogen receptor ligand, can halve the risk of recurrence
and reduce the risk of death by about a quarter in oestrogen
receptor positive patients (EBCTCG, 2005). Benefit is seen in all
patient groups, regardless of age, stage or whether chemotherapy
has been used. The evidence for a mortality benefit from tamoxifen
led to a search for better adjuvant hormonal treatments. The first
trials of highly selective AIs in post-menopausal women began to
report in 2002 (Baum et al, 2002 and Table 1). In contrast to
tamoxifen, which binds to the oestrogen receptor and modulates
its function, the AIs achieve near complete inhibition of oestrone
production, the principal oestrogen in post-menopausal women.
This deprives oestrogen receptor-positive breast cancer cells of
their most important proliferative signal. As the table illustrates,
the AI trials have been among the largest yet seen in breast cancer.
The AI trials have three designs: substitution trials, where an
aromatase inhibitor is given instead of tamoxifen; switching trials,
where 2 to 3 years of tamoxifen and 2 to 3 years of an aromatase
inhibitor are given sequentially for a total of 5 years of hormonal
treatment (tamoxifen has usually been given first in these trials),
and extension trials, where 5 years of tamoxifen treatment is
followed by 2 to 3 years of an aromatase inhibitor. Each of these AI
trials has clearly shown a disease-free survival (DFS) advantage for
the AI. These DFS outcomes were so convincing that by 2005 the
ASCO Technology Assessment Panel had ruled that optimal
adjuvant hormonal therapy should include an AI, ‘but it remains
unclear if initial treatment with an aromatase inhibitor is superior
to a planned cross over from tamoxifen’ (Winer et al, 2005).
Despite the ASCO Panel’s careful wording, most oncologists
concluded that tamoxifen was an inferior drug and should no
longer be used in their post-menopausal patients. Within a few
months Patterns of Care surveys showed that over 80% of
oncologists in North America had stopped using tamoxifen
altogether for post-menopausal patients (Love, 2005). In the light
of these new data, it is now time to consider whether this was the
correct decision.
There is increasing concern that some of the most influential AI
trials have been unable to demonstrate an overall survival (OS)
advantage of AI’s compared with tamoxifen particularly when used
up front. For example Seruga and Tannock recently reviewed the
evidence and concluded that ‘there is no evidence for superiority
of AIs over tamoxifen when used as initial treatment’ (Seruga and
Tannock, 2009). They were undecided about the possible survival
benefit of a switching strategy, conceding only that a recent
metanalysis of the switching trials ‘suggests an advantage’ in
overall survival. Surprisingly this metanalysis (Jonat et al, 2006)
did not include the International Exemestanse Study which ‘was
excluded because it investigated a steroidal aromatase inhibitor’
(Seruga and Tannock, 2009).
Here, we develop the case put by Seruga and Tannock in the
light of fresh evidence, focusing particularly on the case for a
switching strategy. Most of the trials included have been updated
since the meta-analysis, doubling the median follow up time. We
also think that it is legitimate to consider trials that used
exemestane, as many oncologists believe that there is little or no
clinical difference between steroidal and non-steroidal AIs. We will
also consider the statistical pitfalls that confront investigators as
they grapple with the problem of crossover. This has affected
almost all of the AI trials and has confused their reporting.
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trial that compares 5 years of anastrozole to 5 years of tamoxifen
(ATAC Trialists Group, 2008). The ATAC trial showed a
convincing early improvement in disease-free survival for the
anastrozole arm, a finding which generated great interest and led
to the rapid and widespread changes in practice described above.
To date, however, ATAC has failed to show any OS benefit for the
AI arm (ATAC Trialists Group, 2008). Initially these concerns were
dismissed because it can take time for an OS difference to emerge,
but as the follow-up has stretched out to 100 months, this concern
has steadily grown. No OS difference has emerged from the ATAC
study. Indeed there is not even the suggestion of a trend towards
an improved survival advantage.
Two explanations have been offered to explain the lack of an OS
benefit in the ATAC trial. First, longer follow up is needed. Second,
about two-thirds of the patients enrolled into the ATAC study were
node negative, and it has been suggested that their relatively good
baseline prognosis makes it harder to demonstrate a significant
absolute mortality difference. It is equally possible, however, that
the complete substitution of tamoxifen by an AI is not the best way
to use these new drugs. Perhaps there are some patients who need
tamoxifen for their cure.
For patients in their first consultation after surgery for breast
cancer, there is one question, which comes above all others: How
can I reduce my risk of death? If we look at all of the AI data with
this single question in mind, we can see that mortality benefits are
only seen in a subset of trials. We have called these the ‘OS-positive
trials’ (highlighted in Table 1). In one trial (the MA 17 trial), the OS
advantage was seen in a planned subgroup analysis (Goss et al,
2005), but in the other trials this was a prospectively predefined
end point seen in the entire study population. It is striking
that all of the OS-positive trials included a period of tamoxifen
before the AI. Indeed it seems that OS positivity is confined to
trials, which used a sequenced tamoxifen-AI strategy, rather than
an AI alone.
This conclusion is supported by the meta-analysis of AI trials
which was presented at the recent San Antonio meeting (Ingle
et al, 2008b) which examined all of the AI trial data, and divided
patients into two cohorts: those patients who never received
tamoxifen and those who received tamoxifen before taking an AI.
The first cohort is OS negative, whereas the second is OS positive.
Importantly, and in contrast to an earlier metanalysis (Jonat et al,
2006), the Ingle metanalysis includes all aromatase inhibitors of
either the non-steroidal (letrozole and anastrozole) or steroidal
(exemestane) class. It therefore includes the largest switching trial
(the International Exemestane Study), which shows a significant
overall survival benefit.
One important issue that needs to be addressed in the
OS-positive tamoxifen/AI studies is potential bias at the randomi-
sation point. Patients in substitution trials were randomised
shortly after diagnosis, whereas those in switching trials were
randomised at the switch point. If patients are randomised after
they have been on tamoxifen for 2 to 3 years, then a small but
important pool of early relapsing patients, with hormonally
refractory breast cancer, will have been removed from the patient
population. The removal of this poorly responsive group could
account for the ability of AIs to achieve a mortality benefit in the
more hormonally responsive patients who made it through the
first 2 or 3 years to the randomisation point.
The 2008 San Antonio Breast Cancer Symposium included two
large studies, which shed some light on this issue. Before
considering this more fully, we need to acknowledge that the
analysis of some of these trials is complicated by a crossover
problem. The early DFS improvement from AIs were widely
publicised in the early 2000s. It was therefore inevitable that large
numbers of women assigned to tamoxifen in other trials would opt
to withdraw from these studies and cross over to an AI.
Investigators have attempted to deal with the crossover problem
by analysing their data in three different ways, Intent to Treat
(ITT), censored or retrospective. ITT analysis ignores the cross
over and keeps patients in their originally assigned treatment
groups, regardless of whether they are actually taking tamoxifen or
not. This is a statistically rigorous approach, but it may contribute
to an underestimation of the benefits of AIs. The ITT method
therefore may be less informative and less persuasive for changing
clinical practice. Alternatively, censored data can be used. Using
the Kaplan–Meier method, patients are silently removed from the
data set (censored) at the moment that they withdraw themselves
from the control arm of the trial to take an AI. The third approach
is the retrospective analysis in which patients are analysed by what
drug they received rather than how they were initially assigned.
Although censored or retrospective analysis seems to deal with
the problem of cross over, these approaches become problematic if
there is any association between a woman’s desire to leave the
control arm of a trial and her risk of relapse or death. In fact, such
an association is quite likely. For example, one can easily imagine
that a younger woman at higher risk might take more interest in
breast cancer research, including the emerging results from the
ATAC trial, and have a lower threshold for asking to come out of
trial and cross over to the AI arm, whereas older women with lower
risk disease and other comorbidites might be content to remain on
the original assigned treatment.
There is now strong evidence that exactly this kind of crossover
bias does exist. When the MA17 trial reported a DFS advantage for
Table 1 A summary of the AI trials that have been reported to date
n AI Design Age ER+ % n+F U D F S H R
Events
AI/TAM DFS P val OS
Deaths
AI/TAM OS P val ref
ATAC 5216 A sub 64 100 35 100 0.85 618/702 0.003 0.97 472/477 NS 1
BIG 1-98 4922 L sub 61 98 41 76 0.88 509/565 0.03 0.87 303/343 0.08 2
IES 4602 E sw n/s 100 48 56 0.75 339/439 0.0001 0.83 210/251 0.05 3
ABCSG-8 2922 A sw n/s 100 25 72 0.79 202/235 0.038 0.77 130/157 0.025 4
ARNO-95 979 A sw 61 97 25 30 0.66 36/47 0.049 0.53 15/28 0.045 5
ITA/GROCTA 828 A,AG sw 64 100 85 78 not stated 0.61 48/74 0.007 6
NSABP B33 1598 E ext 60 100 48 30 0.68 37/52 0.07 1.0 16/13 NS 7
MA17 5187 L ext 62 97 46 64 0.68 164/235 0.0001 1.0 154/155 NS 8
Abbreviations: sub¼substitution, sw¼switching, ext¼extension. A¼Anastrozole, L¼Letrozole, E¼Exemestane, AG¼Aminogluthemide. Those trials that have a statistically
significant mortality benefit are highlighted in pink. This table clearly shows that only the switching trials have been able to show a mortality benefit from the AIs. Refs: 1¼ATAC
Trialists, 2008; 2¼Mouridsen et al, 2008; 3¼Coombes et al, 2007; 4¼Jakesz et al, 2008; 5¼Kaufmann et al, 2007; 6¼Boccardo et al, 2007; 7¼Mamounas et al, 2008; 8¼
Ingle et al, 2008a. All these analyses are intent to treat (ITT) with no adjustment for crossover and patients are kept in their originally assigned groups even if they crossed over
from the control arm to the investigational arm. However, for the ATAC and IES data presented in this table, the ER unknown or ER-negative patients are excluded from analysis.
For MA17, a 2005 report showed an OS advantage in the node-positive subgroup; this was not seen in the most recent results, probably because of a high crossover rate. For
ATAC, the figure in the table is for the ER-positive subgroup.
Tamoxifen: the drug that came in from the cold
L Hughes-Davies et al
876
British Journal of Cancer (2009) 101(6), 875–878 & 2009 Cancer Research UKletrozole (Goss et al, 2005), patients in the control arm were
informed and offered the option of crossing over. About two-
thirds of the placebo patients opted to cross over. The clinical
course of these placebo patients was recently reported in an update
paper which has become known as the MA17 Unblinding Study
(Goss et al, 2008). This fascinating and detailed study of a mass
crossover event in a large contemporary randomised study offers
deep insights into the many sources of bias which could
contaminate a censored or retrospective analysis. Patients who
opted for the cross over were substantially younger, more likely to
have received chemotherapy and were more frequently node
positive (Goss et al, 2008). These multiple biases are likely to act in
different directions and therefore make a censored analysis
problematic. On one hand, higher risk patients tended to cross
over to the investigational treatment (which favours the control
arm). On the other, older patients tend to prefer to stay on their
assigned control treatment, which would strongly affect the OS
curves (in favour of the investigational treatment).
That these sources of bias are powerful, and can lead to results
which are clearly artefactual, is also shown in the MA17
Unblinding Study (Goss et al, 2008). The retrospective analysis
of outcome generated a highly significant hazard ratio for OS of 0.3
(0.17–0.53) in favour of letrozole. This mortality result is better
than anything we have seen in any therapeutic breast cancer trial
over the past half century, and must simply reflect the older age of
the patients who decided not to cross over rather than any
unprecedented lifesaving effect of letrozole. For these reasons, we
believe that oncologists should not be seduced into using the
(apparently reasonable) censored or retrospective analyses of
trials, which are so often seen as an investigator’s attempt to
salvage trials with a high crossover rate. As a result, ITT (Intention
to Treat) is the only appropriate method that should be used to
analyse the current AI trials.
The larger of the two trials to report at San Antonio 2008 was the
BIG 1–98 study (Mouridsen et al, 2008), a complex trial which
compares both a switching and substitution design to the standard
5 years of tamoxifen. In the ITT analysis, no statistically significant
OS difference was seen between the two monotherapy arms
(tamoxifen alone vs letrozole alone) at 76 months. This trial also
included two switching arms, but OS data has not yet been
reported for this part of the trial, so this is not included in the
table. These latest results from BIG 1–98 reinforce the pattern
previously described: OS positivity is not seen when AIs are given
up front. We predict that an overall survival difference will
eventually be seen in this trial and this will favour a switching
strategy.
The Austrian Breast Cancer Study Group (ABCSG8) trial was
also reported at San Antonio and is one of the most interesting of
the adjuvant AI trials because it shows a clear OS benefit with
shorter follow up than ATAC in a patient population that is
similar. The crossover rate from the tamoxifen arm in this trial was
less than 6%, so the use of a censored method may be legitimate
and, the survival advantage remains significant even if data are
subjected to an ITT analysis (R Jakesz, personal communcation).
ABCSG8 undermines the arguments that have been used to explain
away the lack of a mortality benefit in ATAC. OS positivity was
clearly seen at 72 months, which is 2 years earlier than the ATAC
follow up. Furthermore, the node positivity rates of the patients in
the ABCSG trial are similar to those of ATAC. The mortality
benefits from ABCSG8 suggest that if we treat 60 patients for
6 years, one life will be saved. It is now the fourth OS-positive AI
trial. All four of the OS-positive AI trials have been switching trials.
Or in other words, mortality benefits are only seen in trials, which
give AIs after an initial period of tamoxifen.
In our view, oncologists should always remember the question
that comes before all others. How can an individual patient reduce
her risk of death? The available evidence for receptor-positive
post-menopausal women strongly supports the use of an approach
in which all patients are exposed to 2–3 years of tamoxifen and
2–3 years of an aromatase inhibitor. All OS-positive trials use such
an approach and this is the only treatment strategy for which a
mortality benefit could be seen in the AI meta-analysis. Such an
approach also limits the patient’s exposure to either class of drug.
As these two classes of drug have different safety profiles
(tamoxifen is associated with small risks of endometrial cancer
and thromboembolic disease whereas the AI’s have a moderate
effect on bone health) this additional limited exposure to either
agent is likely to mitigate the risk of serious complications.
CONCLUSION
Recent trial data support the view that AIs should be used after
2–3 years of tamoxifen to achieve an OS advantage and add weight
to scepticism surrounding up front use of these drugs (Seruga and
Tannock, 2009), a strategy which we believe should only be used
for women with contraindications to tamoxifen.
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